What guidance did Nautilus's management provide for the next earnings period?

What were the key takeaways from Nautilus’s earnings call?

What were the key takeaways from Nautilus's earnings call?

What does Nautilus do and what are its main business segments?

What is the market's earnings forecast for Nautilus next quarter?

What factors drove the changes in Nautilus's revenue and profit?

What is Nautilus's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Nautilus year over year?

- **Revenue Trends**: 2025 operating expenses down 18% to $66.8M; 2026 cash burn expected at $65-70M with modest service revenue.
- **Technical Progress**: Broadscale assay on-target binding improved; Tau assay meets commercial readiness criteria.
- **Strategic Moves**: $1.6M MJFF collaboration for Parkinson's research; oncology assay expansion planned for 2026.
- **Customer Engagement**: Early access program launched with academic partners; instrument beta testing underway.
- **Financial Health**: $156M cash runway; no salesforce yet, with commercial launch targeting late 2026.

**【CEO Summary Section】**
- Launched Early Access Program for Tau proteoform assay in January 2026, with initial customer engagement from academic researchers.
- Unveiled Voyager instrument at US HUPO conference, receiving positive feedback on design and biological insights.
- Announced $1.6M collaboration with Michael J. Fox Foundation for alpha-synuclein proteoform assay development.
- Plans to expand into oncology-focused proteoform assays by late 2026.

**【CFO Financial Commentary】**
- Total operating expenses decreased 18% YoY to $66.8M, driven by 19% R&D reduction and 17% G&A decline.
- Ended Q4 with $156.1M cash, expecting 2026 cash burn of $65-70M.
- Anticipates modest 2026 revenue from grant funding and early access services, with commercial launch in late 2026.

**【Q&A Highlights】**
- Technical milestones include improved on-target binding in broadscale assay and stable chip performance.
- Customer feedback highlights data quality and biological insights, with plans for instrument beta deployments.
- CFO reaffirms 2027 commercial launch timeline with instrument preorders and service revenue ramp.
- Management emphasizes disciplined spending and focus on platform validation with key collaborators.

Nautilus Biotechnology, Inc.(NAUT)-20260226-2025 Q4 Earnings call transcript

- **Tau Proteoform Assay Launch**: Early access begins H1 2026, with broadscale proteomics launching late 2026, supported by $168.5M cash runway.
- **Market Validation**: 250+ customer interviews confirm Nautilus' iterative mapping as a disruptive, premium solution over mass spectrometry.
- **Operational Efficiency**: Q3 2025 OpEx down 19% YoY to $15.5M, with disciplined spending extending cash runway to 2027.
- **Commercial Momentum**: Collaborations with top institutions (Allen, Buck) generate real-world data, positioning Nautilus for biomarker discovery in Alzheimer's.

**【CEO Summary Section】**
- **Scientific and Collaborative Progress**: Q3 2025 saw advancements in the Tau proteoform assay, with collaborations at the Allen Institute and Buck Institute generating real-world biological data. Dr. Birgit Schilling will present Nautilus-generated Tau data at the World HUPO Conference in November.
- **Platform Differentiation**: The iterative mapping method enables single-molecule proteoform resolution, validated by 250+ customer interviews that highlighted its superiority over mass spectrometry.
- **Operational Efficiency**: Q3 expenses decreased 19% YoY to $15.5M, extending cash runway to 2027. Early access for Tau begins H1 2026, with broadscale proteomics launching late 2026.

**【CFO Financial Commentary】**
- **Financial Health**: Q3 net loss of $13.6M reflects reduced R&D and G&A expenses. Cash balance of $168.5M supports commercialization efforts.
- **Cost Management**: Stock-based compensation and lab costs declined, with OpEx expected to rise post-2025 as commercial activities accelerate.
- **Revenue Outlook**: Early access engagements (H1 2026) focus on data generation for grants; limited revenue anticipated in 2026.

**【Q&A Key Highlights】**
- **OpEx Trajectory**: CFO Anna Mowry expects OpEx to increase post-Q3 2025 as commercialization ramps up, with no 2026 guidance yet.
- **Funnel Development**: CEO Sujal Patel detailed a two-phase early access launch (Tau H1 2026, broadscale H2 2026), with direct sales hires planned for Tau services.
- **Market Validation**: Customer willingness to pay a premium for iterative mapping validates Nautilus' premium positioning in proteomics.


Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript

- **Breakthrough Proteoform Technology**: Nautilus platform achieves 1.5% within-run reproducibility and quantifies proteoforms at 0.1% abundance, identifying 130 tau proteoforms in human samples.
- **Strong Academic & Pharma Interest**: Over 8,000 researchers engaged at AAIC, with pharma expressing interest in pilot studies to integrate proteoform data into drug development.
- **Financial Discipline**: 18% YoY expense reduction to $17.1M, with $179.5M cash runway through 2027. Broadscale proteomics launch in 2026 expected to drive rapid revenue growth.
- **Strategic Balance**: Prioritizing platform optimization while maintaining flexibility to monetize proteoform insights through collaborations or direct assays.

**【CEO Opening Remarks】**
- Q2 marked a milestone with the release of a preprint manuscript showcasing the Nautilus platform's ability to resolve proteoforms at single-molecule resolution. This work, conducted in collaboration with Genentech, Neural Stem Cell Institute, and Mount Sinai, validates the platform's technical rigor and biological impact.
- The manuscript demonstrates the platform's industry-leading reproducibility (median CV of 1.5% within-run, 5% across runs) and sensitivity, quantifying proteoforms at 0.1% abundance levels. Early biological insights suggest potential new mechanisms in tau biology, opening pathways for neurodegenerative disease diagnostics and therapeutics.
- The company signed 2 collaborations with U.S. research institutes to demonstrate platform capabilities and enable new biological insights, though these are not revenue-generating in the near term.

**【Chief Scientist (Parag Mallick) Technical Update】**
- The iterative mapping method enables end-to-end proteoform analysis from sample to quantification, with no existing platform capable of matching its resolution or sensitivity. Traditional methods (e.g., Olink, mass spectrometry) lose co-occurrence data or require peptide fragmentation, making them unsuitable for proteoform analysis.
- The platform's dynamic range (1,000x) and reproducibility (5% CV across labs) are superior to existing proteomics tools. In tau studies, the platform identified 130 distinct proteoforms, including forms with 6 simultaneous phosphorylation events, which were previously undetectable.
- Human cohort analysis revealed a quadruply phosphorylated tau form uniquely associated with aggressive Alzheimer's, suggesting potential biomarkers for disease staging and progression.

**【CFO (Anna Mowry) Financial Update】**
- Q2 2025 operating expenses: $17.1M (18% YoY decrease), driven by headcount reduction and cost optimization. R&D: $10.4M (-16% YoY), G&A: $6.7M (-20% YoY). Net loss: $15.0M (17% YoY improvement). Cash balance: $179.5M, providing runway through 2027.
- Expect steady R&D spending in H2 2025, with total annual expenses below 2024 levels. Focus on balancing resource allocation between targeted proteoform assays and broadscale proteomics development.

**【Q&A Highlights】**
- **Market Reaction & Publication Plans**: Strong academic and pharma interest in proteoform data, with researchers describing it as a "fundamentally different way of understanding biology." Manuscript under peer review for high-impact journals; publication timing TBD.
- **Revenue Outlook**: Broadscale proteomics (planned 2026 launch) expected to generate faster revenue growth due to existing market demand. Proteoform assays will require longer market development but have multi-hundred million dollar potential over 5-7 years.
- **Probe Optimization**: Transitioning to new assay configuration to improve probe yield; initial data promising but specific performance metrics to be shared in future quarters.
- **Collaboration Strategy**: Balancing early academic partnerships with pharma pilots to demonstrate therapeutic relevance, while preserving optionality for future business models (e.g., data sharing vs. therapeutic collaborations).

Nautilus Biotechnology (NAUT)-31 Jul 25-2025 Q2 Earnings call transcript

- **Technical Breakthrough**: Tau assay V&V achieves 10% accuracy error and 1.5% CV, enabling single-molecule proteoform resolution in AD research.
- **Partnership Momentum**: On track to announce first tau-related partnership in Q2, targeting non-profit/academic collaborators.
- **Financial Health**: 13% YoY expense reduction to $18.8M, with $193M cash runway supporting 2026 commercial launch.
- **Market Validation**: Customer interviews confirm platform's unique value in proteoform analysis, aligning with 2026 launch timeline.

**【CEO Summary Section】**
- **Q1 Progress**: Advanced targeted proteoform detection with tau assay verification/validation (V&V) exceeding expectations. Achieved 10% median accuracy error and 1.5% CV across runs, surpassing 20% target. Demonstrated compatibility with 12 affinity reagents and 4,096 potential proteoforms.
- **Customer Engagement**: Conducted 30+ researcher interviews, revealing strong interest in proteoform analysis for drug discovery and biomarker development. Alzheimer's disease pilot study revealed novel phosphorylation patterns unobservable with current methods.
- **Partnership Outlook**: Anticipate signing first tau-related partnership in Q2, likely with non-profit or academic institutions, as pharma requires more data publication.

**【Chief Scientist Update】**
- **V&V Results**: Platform dynamic range exceeded four orders of magnitude, outperforming TMT-based methods. Tested with 10µg total protein input (0.03% tau) across human cell lines, organoids, and AD brain samples.
- **AD Research**: Identified complex phosphorylation patterns in aggressive AD cases, suggesting potential biomarkers for disease progression and therapeutic targeting.
- **Platform Maturity**: Instrument and software reliability exceeded 80%, with accelerated software pipelines ready for commercial launch in late 2026.

**【CFO Financials】**
- **Cost Efficiency**: Q1 2025 operating expenses $18.8M (-13% YoY), driven by headcount reduction (16%) and optimized R&D spend. Net loss $16.6M (-11% YoY).
- **Cash Position**: $193M cash runway extending to 2027, supporting development through commercial launch.

**【Q&A Highlights】**
- **Supply Chain Resilience**: Diversified sourcing mitigates tariff risks; no material impact on current operations.
- **Business Model Exploration**: Evaluating service-based pricing and joint development agreements, prioritizing education over near-term revenue.
- **Market Confidence**: Customer interviews confirm platform value proposition, with 2026 launch expectations unchanged despite market shifts.

Nautilus Biotechnology (NAUT)-29 Apr 25-2025 Q1 Earnings call transcript

- **Launch Delayed to 2026**: Platform release pushed to late 2026 due to technical optimizations, extending cash runway to 2027.
- **Key 2025 Milestones**: Tau proteoform assay access, partnerships, and broad-scale protein decoding progress.
- **Financial Discipline**: 16% headcount reduction maintains 2024 expense levels, cash balance at $206 million.
- **Unique Tech Specs**: 3+ orders of magnitude dynamic range, high-resolution proteoform measurement, and single-molecule specificity.
- **Partnership Focus**: 2025 collaborations centered on tau, with potential expansion to other biomarkers.


**【CEO Summary Section】**
- Nautilus expects the launch of its proteome analysis platform in late 2026, delayed due to technical optimizations in assay configuration and surface chemistry.
- Key 2025 milestones include providing researchers access to tau proteoform assays, signing partnerships, and advancing broad-scale proteomics capabilities.
- The company reduced headcount by 16% to extend cash runway through 2027, maintaining operating expenses at 2024 levels.

**【CFO Financial Commentary】**
- Q4 2024 operating expenses: $20.0 million (flat YoY), net loss: $17.6 million.
- FY 2024 total operating expenses: $81.5 million (+7% YoY), net loss: $70.8 million (+11% YoY).
- Cash balance: $206 million as of Q4 2024, extended to 2027 post-headcount reduction.

**【Q&A Key Highlights】**
- **Platform monetization**: Instrument bundle pricing remains at $1 million, with sample costs starting at $2,000+ per sample.
- **Technical challenges**: Surface chemistry and probe labeling optimizations aim to reduce nonspecific binding and improve probe yield.
- **Competitive differentiation**: Unique ability to measure high-resolution tau proteoforms in complex samples, with 3+ orders of magnitude dynamic range.
- **Partnership strategy**: Focused on tau-related collaborations in 2025, with potential expansion to other biomarkers.
- **Early access program**: Expected to begin 6-9 months prior to late 2026 commercial launch, targeting instrument placements.

**【R&D Progress】**
- **Broad-scale proteomics**: Progressed probe library characterization, with multi-affinity probes demonstrating ability to differentiate proteins at single-molecule level.
- **Targeted proteoforms**: Achieved high-accuracy tau proteoform quantification, including phosphorylation states, with CV <20%.
- **Instrument stability**: Improved reagent production scale, multi-cycle binding detection, and data processing pipelines.


Nautilus Biotechnology (NAUT)-27 Feb 25-2024 Q4 Earnings call transcript

Nautilus Biotechnology (NAUT)-29 Oct 24-2024 Q3 Earnings call transcript

Nautilus Biotechnology (NAUT)-30 Jul 24-2024 Q2 Earnings call transcript

Nautilus Biotechnology (NAUT)-30 Apr 24-2024 Q1 Earnings call transcript

Nautilus Biotechnology (NAUT)-28 Feb 24-2023 Q4 Earnings call transcript

Nautilus Biotechnology (NAUT)-31 Oct 23-2023 Q3 Earnings call transcript

- **2024 Launch Target**: V1 platform set for mid-2024, with specs prioritizing sensitivity, ease of use, and dynamic range.
- **Technical Progress**: Q2 saw chip scale-up, reagent yield improvements, and 150-cycle assay validation.
- **Financial Strength**: $287M cash runway to 2026; 2023 expenses +30% YoY, supporting rapid iteration post-launch.
- **Market Momentum**: Strong customer interest, with early access program beginning late 2023.
- **Competitive Edge**: Unique single-molecule intact protein analysis outperforms traditional methods in confidence and scalability.

**【CEO Summary Section】**
- Celebrated two years since NASDAQ listing, highlighting progress in platform development and cash runway management.
- Targeted mid-2024 commercial launch with V1 specs focused on non-negotiable features: single-molecule sensitivity, ease of use, and high dynamic range.
- Early Access Program (EAP) to begin in late 2023, prioritizing data generation and customer engagement over revenue.
- Emphasized rapid iteration post-launch, akin to Illumina's Genome Analyzer trajectory, with consumable updates enabling future spec enhancements.

**【CTO/Chief Scientist Technical Update】**
- Q2 advancements include:
  - Chip fabrication scale-up to manufacturing facility in San Carlos.
  - Reagent development yield improvements, supporting 150-cycle experiments.
  - Enhanced assay stability and scalability, enabling larger probe libraries.
  - Instrument validation progressing toward commercial readiness.
- Model system experiments expanded to include complex protein mixes, nearing customer sample-like inputs.

**【CFO Financial Commentary】**
- Q2 2023: $19.0M operating expenses ($15.8M net loss), $287M cash balance.
- 2023 guidance: ~30% YoY expense growth vs. 2022, extending cash runway to 2026.
- Revenue expectations: modest 2024 EAP contributions, meaningful growth from 2025 instrument sales and consumables.
- No debt; prioritizing platform completion and commercial readiness.

**【Q&A Highlights】**
- **Competitive Positioning**: Differentiated by single-molecule intact protein analysis, high confidence identifications, and ease of use vs. mass spec and peptide sequencing.
- **V1 Specs Flexibility**: Sample input and protein count flexibility, while maintaining game-changing specs on sensitivity and dynamic range.
- **Customer Interest**: Strong demand from proteomics KOLs and researchers, with early access participants tracking.
- **ASMS Response**: Excited by mass spec advancements but reiterating Nautilus' unique value in overcoming traditional proteomics limitations.


Actual	-0.19	-0.12	-0.13	-0.13	-0.12	-0.11	-0.11	-0.12	-0.13	-0.13	-0.14	-0.15	-0.14	-0.13	-0.14	-0.13	-0.12	-0.11	-0.11
Forecast	-0.07	-0.1033	-0.1325	-0.1575	-0.1675	-0.1475	-0.1525	-0.1625	-0.15	-0.155	-0.1575	-0.1625	-0.164	-0.165	-0.153	-0.146	-0.155	-0.15	-0.14
Surprise	-171.43%	-16.17%	+1.89%	+17.46%	+28.36%	+25.42%	+27.87%	+26.15%	+13.33%	+16.13%	+11.11%	+7.69%	+14.63%	+21.21%	+8.50%	+10.96%	+22.58%	+26.67%	+21.43%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	0	0	0	166.67K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

NAUT

NAUT fundamentals

NAUT Q4 2025 Earnings

Earnings Call

You can ask Aime

NAUT

NAUT fundamentals

NAUT Q4 2025 Earnings

Earnings Call

NAUT Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

NAUT Earnings Call Summary for Q3/20258:30 AM on Oct 28, 2025

NAUT Earnings Call Summary for Q2/20258:30 AM on Jul 31, 2025

NAUT Earnings Call Summary for Q1/20258:30 AM on Apr 29, 2025

NAUT Earnings Call Summary for Q4/20248:30 AM on Feb 27, 2025

You can ask Aime